News

Published on 3 Mar 2024 on Simply Wall St. via Yahoo Finance

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts


Article preview image

Celebrations may be in order for MannKind Corporation (NASDAQ:MNKD) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. Investors have been pretty optimistic on MannKind too, with the stock up 27% to US$4.50 over the past week. Could this upgrade be enough to drive the stock even higher?

Following the upgrade, the latest consensus from MannKind's six analysts is for revenues of US$284m in 2024, which would reflect a major 43% improvement in sales compared to the last 12 months. Losses are expected to turn into profits real soon, with the analysts forecasting US$0.20 in per-share earnings. Prior to this update, the analysts had been forecasting revenues of US$246m and earnings per share (EPS) of US$0.088 in 2024. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates.

Check out our latest analysis for MannKind

NASDAQ.MNKD price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the...

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be...

Simply Wall St. · via Yahoo Finance 3 Feb 2025

Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we ...

Insider Monkey · via Yahoo Finance 6 Jan 2025

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Stock

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developin...

Insider Monkey · via Yahoo Finance 21 Sep 2024

Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And...

Key Insights MannKind will host its Annual General Meeting on 15th of MayCEO Michael Castagna's t...

Simply Wall St. via Yahoo Finance 9 May 2024

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript May 8, 2024 MannKind Corporat...

Insider Monkey via Yahoo Finance 9 May 2024

MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be...

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be ...

Simply Wall St. via Yahoo Finance 2 Apr 2024

MannKind to present new inhaled insulin study data at ATTD By Investing.com

MannKind to present new inhaled insulin study data at ATTD

Investing.com 5 Mar 2024

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts

Celebrations may be in order for MannKind Corporation (NASDAQ:MNKD) shareholders, with the analys...

Simply Wall St. via Yahoo Finance 3 Mar 2024

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript February 27, 2024 MannKind Co...

Insider Monkey via Yahoo Finance 29 Feb 2024

MannKind (MNKD) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool. MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m...

Motley Fool via Yahoo Finance 28 Feb 2024